- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sciences, EyePoint Pharma
Journal: ILUVIEN technology in the treatment of center-involving diabetic macular edema: a review of the literature. (Pubmed Central) - Apr 30, 2019 Recent adoption of novel alternative drug delivery options has led to the development of sustained release ocular implants with longer duration of action with less injection frequency. This article will review the pharmacology and clinical data in terms of efficacy, safety and benefits of the sustained release steroid implants in treatment of DME with special emphasis on the fluocinolone acetonide ILUVIEN implant.
- |||||||||| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Eylea (aflibercept intravitreal) / Bayer, Regeneron
Clinical: Spent the day with this cutie with me at work! Lasik, prk, yags, cataracts (47), premium lenses, femto, MIGS, Dexycu, and a glaucoma device study patient... a… https://t.co/vmk2DTeNZj (Twitter) - Apr 25, 2019
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment closed, Enrollment change, Trial primary completion date: IRISS: Iluvien Registry Safety Study (clinicaltrials.gov) - Oct 25, 2017 P=N/A, N=559, Active, not recruiting, The FAc 0.2 μg/day implant provided good value for money compared with other established treatments, especially in pseudophakic patients. Recruiting --> Active, not recruiting | N=800 --> 559 | Trial primary completion date: Dec 2018 --> Jan 2020
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Trial primary completion date: Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study (clinicaltrials.gov) - Aug 22, 2017 P4, N=0, Withdrawn, Recruiting --> Active, not recruiting | N=800 --> 559 | Trial primary completion date: Dec 2018 --> Jan 2020 Trial primary completion date: Mar 2019 --> Aug 2017
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study (clinicaltrials.gov) - Apr 4, 2017 P4, N=0, Withdrawn, Initiation date: Aug 2006 --> Feb 2016 | Trial primary completion date: Apr 2017 --> Mar 2018 N=50 --> 0 | Initiation date: Sep 2016 --> Mar 2017 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Mar 2019
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Trial completion: RESPOND: A Pilot Study on the Effect and Safety of Iluvien (clinicaltrials.gov) - Mar 10, 2017 P4, N=12, Completed, N=50 --> 0 | Initiation date: Sep 2016 --> Mar 2017 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Mar 2019 Active, not recruiting --> Completed
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment closed, P4 data, Enrollment change, Trial primary completion date: PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) - Jan 6, 2017 P4, N=153, Active, not recruiting, Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=300 --> 153 | Trial primary completion date: Apr 2019 --> Dec 2019
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment status, P4 data: PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) - Mar 31, 2016 P4, N=300, Enrolling by invitation, Enrolling by invitation --> Active, not recruiting | N=300 --> 153 | Trial primary completion date: Apr 2019 --> Dec 2019 Recruiting --> Enrolling by invitation
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment change, Trial termination: Observational Study to Assess the Effect of Iluvien (clinicaltrials.gov) - Aug 11, 2015 P=N/A, N=25, Terminated, Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 N=500 --> 25 | Active, not recruiting --> Terminated
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment closed: Observational Study to Assess the Effect of Iluvien (clinicaltrials.gov) - Jun 6, 2015 P=N/A, N=500, Active, not recruiting, N=500 --> 25 | Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment open, P4 data, Phase classification: PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) - May 22, 2015 P4, N=300, Recruiting, N=40 --> 17 Phase classification: P=N/A --> P4 | Not yet recruiting --> Recruiting
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
New P4 trial, P4 data: PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) - Apr 28, 2015 P4, N=300, Recruiting, Phase classification: P=N/A --> P4 | Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment closed, Enrollment open: RESPOND: A Pilot Study on the Effect and Safety of Iluvien (clinicaltrials.gov) - Mar 19, 2015 P4, N=12, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment open: IRISS: Iluvien Registry Safety Study (clinicaltrials.gov) - Apr 7, 2014 P=N/A, N=800, Recruiting, Trial primary completion date: Dec 2014 --> Apr 2017 Not yet recruiting --> Recruiting
- |||||||||| Medidur (fluocinolone acetonide micro-insert intravitreal implant) / EyePoint Pharma, Alimera Sci
Enrollment closed: Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy (clinicaltrials.gov) - Nov 19, 2013 P2, N=40, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Trial termination, Surgery: Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients (clinicaltrials.gov) - Sep 15, 2013 P2, N=42, Terminated, Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Study C11-01 started
|